Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Diabetes

Free Subscription Articles published in N Engl J Med Retrieve available abstracts of 147 articles: HTML format

Single Articles

November 2024
1. BI Y, Li M, Liu Y, Li T, et al
   Intensive Blood-Pressure Control in Patients with Type 2 Diabetes.
   N Engl J Med. 2024 Nov 16. doi: 10.1056/NEJMoa2412006.
   PubMed     Abstract available
   
   
   
2. RUBIN EJ, Leopold J, Morrissey S
   NEJM at AHA - Intensive Blood-Pressure Control in Patients with Type 2 Diabetes.
   N Engl J Med. 2024 Nov 16. doi: 10.1056/NEJMe2414476.
   PubMed    
   
   
   
3. JASTREBOFF AM, le Roux CW, Stefanski A, Aronne LJ, et al
   Tirzepatide for Obesity Treatment and Diabetes Prevention.
   N Engl J Med. 2024 Nov 13. doi: 10.1056/NEJMoa2410819.
   PubMed     Abstract available
   
   
   
4. PERKOVIC V, Tuttle KR, Pratley R
   Semaglutide for Chronic Kidney Disease in Type 2 Diabetes. Reply.
   N Engl J Med. 2024;391:1757.
   PubMed    
   
   
   
5. DA HORA PASSOS R, Narciso RC, da Silva AA
   Semaglutide for Chronic Kidney Disease in Type 2 Diabetes.
   N Engl J Med. 2024;391:1757.
   PubMed    
   
   
   October 2024
6. ISRAEL A, Vinker S, Merzon E
   More on Type 2 Diabetes in Patients with G6PD Deficiency. Reply.
   N Engl J Med. 2024;391:1664.
   PubMed    
   
   
   
7. CUI W
   More on Type 2 Diabetes in Patients with G6PD Deficiency.
   N Engl J Med. 2024;391:1664.
   PubMed    
   
   
   September 2024
8. WYSHAM C, Bajaj HS, Del Prato S, Franco DR, et al
   Insulin Efsitora versus Degludec in Type 2 Diabetes without Previous Insulin Treatment.
   N Engl J Med. 2024 Sep 10. doi: 10.1056/NEJMoa2403953.
   PubMed     Abstract available
   
   
   August 2024
9. PERSAD G, Dellgren JL, Emanuel EJ
   Fair Allocation of GLP-1 and Dual GLP-1-GIP Receptor Agonists. Reply.
   N Engl J Med. 2024;391:776.
   PubMed    
   
   
   
10. GONG JY, Shaw JE
    Fair Allocation of GLP-1 and Dual GLP-1-GIP Receptor Agonists.
    N Engl J Med. 2024;391:775-776.
    PubMed    
    
    
    
11. MENSAH MO, Freitas DJ, Cartwright JR
    Fair Allocation of GLP-1 and Dual GLP-1-GIP Receptor Agonists.
    N Engl J Med. 2024;391:775.
    PubMed    
    
    
    
12. MAKARY N, Razali Q
    Diabetes-Associated Scleredema.
    N Engl J Med. 2024;391:e15.
    PubMed    
    
    
    
13. ISRAEL A, Raz I, Vinker S, Magen E, et al
    Type 2 Diabetes in Patients with G6PD Deficiency.
    N Engl J Med. 2024;391:568-569.
    PubMed    
    
    
    July 2024
14. KOSIBOROD MN, Petrie MC, Borlaug BA
    Semaglutide, Obesity-Related Heart Failure, and Type 2 Diabetes. Reply.
    N Engl J Med. 2024;391:381-382.
    PubMed    
    
    
    
15. AMMON JP, Jackson CD
    Semaglutide, Obesity-Related Heart Failure, and Type 2 Diabetes.
    N Engl J Med. 2024;391:381.
    PubMed    
    
    
    
16. WAGNER J
    Semaglutide, Obesity-Related Heart Failure, and Type 2 Diabetes.
    N Engl J Med. 2024;391:380-381.
    PubMed    
    
    
    
17. COHEN C, Cohen R, Sabouret P
    Semaglutide, Obesity-Related Heart Failure, and Type 2 Diabetes.
    N Engl J Med. 2024;391:380.
    PubMed    
    
    
    
18. HERRINGTON WG, Haynes R
    Diabetic Kidney Disease - Semaglutide Flows into the Mainstream.
    N Engl J Med. 2024;391:178-179.
    PubMed    
    
    
    June 2024
19. MANRIQUE-ACEVEDO C, Hirsch IB, Eckel RH
    Prevention of Cardiovascular Disease in Type 1 Diabetes. Reply.
    N Engl J Med. 2024;390:2227.
    PubMed    
    
    
    
20. MAAHS DM, Svensson J
    Prevention of Cardiovascular Disease in Type 1 Diabetes.
    N Engl J Med. 2024;390:2226-2227.
    PubMed    
    
    
    
21. WENSTEDT EFE, Vogt L
    Prevention of Cardiovascular Disease in Type 1 Diabetes.
    N Engl J Med. 2024;390:2226.
    PubMed    
    
    
    
22. CEFALU WT, Arreaza-Rubin G
    Engineering an Insulin Complex to Treat Diabetes.
    N Engl J Med. 2024;390:2214-2216.
    PubMed    
    
    
    
23. ROY N, Mandal M
    Insulin-Induced Lipohypertrophy.
    N Engl J Med. 2024;390:e60.
    PubMed    
    
    
    May 2024
24. BICHET DG, Bockenhauer D
    Thirst, Hunger, and Nephrogenic Diabetes Insipidus.
    N Engl J Med. 2024;390:1922-1924.
    PubMed    
    
    
    
25. EMANUEL EJ, Dellgren JL, McCoy MS, Persad G, et al
    Fair Allocation of GLP-1 and Dual GLP-1-GIP Receptor Agonists.
    N Engl J Med. 2024;390:1839-1842.
    PubMed    
    
    
    
26. PERKOVIC V, Tuttle KR, Rossing P, Mahaffey KW, et al
    Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.
    N Engl J Med. 2024 May 24. doi: 10.1056/NEJMoa2403347.
    PubMed     Abstract available
    
    
    April 2024
27. KOSIBOROD MN, Petrie MC, Borlaug BA, Butler J, et al
    Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes.
    N Engl J Med. 2024 Apr 6. doi: 10.1056/NEJMoa2313917.
    PubMed     Abstract available
    
    
    
28. BUTLER J, Jones WS, Udell JA, Anker SD, et al
    Empagliflozin after Acute Myocardial Infarction.
    N Engl J Med. 2024 Apr 6. doi: 10.1056/NEJMoa2314051.
    PubMed     Abstract available
    
    
    
29. MANRIQUE-ACEVEDO C, Hirsch IB, Eckel RH
    Prevention of Cardiovascular Disease in Type 1 Diabetes.
    N Engl J Med. 2024;390:1207-1217.
    PubMed    
    
    
    
30. VAZQUEZ MA, Oliver G, Amarasingham R, Sundaram V, et al
    Pragmatic Trial of Hospitalization Rate in Chronic Kidney Disease.
    N Engl J Med. 2024;390:1196-1206.
    PubMed     Abstract available
    
    
    
31. FOURMAN LT, Tsai LL, Brown RJ, O'Rahilly S, et al
    Case 10-2024: A 46-Year-Old Woman with Hyperglycemia Refractory to Insulin Therapy.
    N Engl J Med. 2024;390:1219-1229.
    PubMed    
    
    
    March 2024
32. HUGHES MS, Addala A, Buckingham B
    Digital Technology for Diabetes. Reply.
    N Engl J Med. 2024;390:963-964.
    PubMed    
    
    
    
33. BERG TJ
    Digital Technology for Diabetes.
    N Engl J Med. 2024;390:963.
    PubMed    
    
    
    
34. TUMMINIA A, Gullo D, Frasca F
    Digital Technology for Diabetes.
    N Engl J Med. 2024;390:962-963.
    PubMed    
    
    
    
35. KINNY-KOSTER B, Michalski CW, Loos M
    Digital Technology for Diabetes.
    N Engl J Med. 2024;390:962.
    PubMed    
    
    
    February 2024
36. LINCOFF AM, Ryan DH, Esbjerg S
    Semaglutide and Cardiovascular Outcomes. Reply.
    N Engl J Med. 2024;390:768-769.
    PubMed    
    
    
    
37. NEVES JS, Leite AR, Ferreira JP
    Semaglutide and Cardiovascular Outcomes.
    N Engl J Med. 2024;390:767-768.
    PubMed    
    
    
    
38. CAMPBELL LA, Jenkins AV, Jackson CD
    Semaglutide and Cardiovascular Outcomes.
    N Engl J Med. 2024;390:767.
    PubMed    
    
    
    
39. BELKHOURIBCHIA J
    Semaglutide and Cardiovascular Outcomes.
    N Engl J Med. 2024;390:767.
    PubMed    
    
    
    
40. BELALCAZAR LM, Kuo YF
    Semaglutide and Cardiovascular Outcomes.
    N Engl J Med. 2024;390:766-767.
    PubMed    
    
    
    
41. TAQUETI VR, Shaw LJ
    Semaglutide and Cardiovascular Outcomes.
    N Engl J Med. 2024;390:766.
    PubMed    
    
    
    
42. SCHWARTZ AL
    SGLT2 Inhibitors and False Positive Toxicology Tests.
    N Engl J Med. 2024;390:573-574.
    PubMed    
    
    
    January 2024
43. DANDONA P, Chaudhuri A, Ghanim H
    More on Semaglutide in Early Type 1 Diabetes. Reply.
    N Engl J Med. 2024;390:292.
    PubMed    
    
    
    
44. GAGLIA JL, Laffel LM, Patti ME
    More on Semaglutide in Early Type 1 Diabetes.
    N Engl J Med. 2024;390:291.
    PubMed    
    
    
    
45. WEINRAUCH LA, D'Elia JA
    More on Semaglutide in Early Type 1 Diabetes.
    N Engl J Med. 2024;390:291.
    PubMed    
    
    
    
46. DEVRIES JH
    More on Semaglutide in Early Type 1 Diabetes.
    N Engl J Med. 2024;390:290.
    PubMed    
    
    
    
47. LEE TTM, Bergford S, Murphy HR
    Automated Insulin Delivery during Pregnancy Complicated by Type 1 Diabetes. Reply.
    N Engl J Med. 2024;390:184.
    PubMed    
    
    
    
48. GRZYCH G, Kim I
    Automated Insulin Delivery during Pregnancy Complicated by Type 1 Diabetes.
    N Engl J Med. 2024;390:183-184.
    PubMed    
    
    
    
49. VIVANTI AJ, Benachi A, Voican A
    Automated Insulin Delivery during Pregnancy Complicated by Type 1 Diabetes.
    N Engl J Med. 2024;390:183.
    PubMed    
    
    
    
50. LIU MJ, Li J
    Necrobiosis Lipoidica.
    N Engl J Med. 2024;390:70.
    PubMed    
    
    
    December 2023
51. WHARTON S, Konig M
    GLP-1 Receptor Agonist Orforglipron for Adults with Obesity. Reply.
    N Engl J Med. 2023;389:2304-2305.
    PubMed    
    
    
    
52. POURKARIM F, Entezari-Maleki T
    GLP-1 Receptor Agonist Orforglipron for Adults with Obesity.
    N Engl J Med. 2023;389:2303-2304.
    PubMed    
    
    
    
53. PRESTON W
    GLP-1 Receptor Agonist Orforglipron for Adults with Obesity.
    N Engl J Med. 2023;389:2303.
    PubMed    
    
    
    
54. LUDVIGSSON J
    Immune Interventions at Onset of Type 1 Diabetes - Finally, a Bit of Hope.
    N Engl J Med. 2023;389:2199-2201.
    PubMed    
    
    
    
55. WAIBEL M, Wentworth JM, So M, Couper JJ, et al
    Baricitinib and beta-Cell Function in Patients with New-Onset Type 1 Diabetes.
    N Engl J Med. 2023;389:2140-2150.
    PubMed     Abstract available
    
    
    November 2023
56. HUGHES MS, Addala A, Buckingham B
    Digital Technology for Diabetes.
    N Engl J Med. 2023;389:2076-2086.
    PubMed    
    
    
    
57. VIVANTE A, Tan W, Harrington SG, Udler MS, et al
    Case 36-2023: A 19-Year-Old Man with Diabetes and Kidney Cysts.
    N Engl J Med. 2023;389:1993-2003.
    PubMed    
    
    
    
58. NEWELL-PRICE J
    Testing for Arginine Vasopressin Deficiency.
    N Engl J Med. 2023;389:1920-1921.
    PubMed    
    
    
    
59. LINCOFF AM, Brown-Frandsen K, Colhoun HM, Deanfield J, et al
    Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.
    N Engl J Med. 2023 Nov 11. doi: 10.1056/NEJMoa2307563.
    PubMed     Abstract available
    
    
    October 2023
60. ROSENSTOCK J, Gowda A, Liang B
    Weekly Icodec versus Daily Glargine U100 in Type 2 Diabetes without Previous Insulin. Reply.
    N Engl J Med. 2023;389:1533.
    PubMed    
    
    
    
61. MISBIN RI
    Weekly Icodec versus Daily Glargine U100 in Type 2 Diabetes without Previous Insulin.
    N Engl J Med. 2023;389:1532-1533.
    PubMed    
    
    
    
62. SUGIYAMA K
    Weekly Icodec versus Daily Glargine U100 in Type 2 Diabetes without Previous Insulin.
    N Engl J Med. 2023;389:1532.
    PubMed    
    
    
    
63. ABEL ED, Ingelfinger JR, Linhales Barker S, Peek M, et al
    Type 2 Diabetes - Controlling the Epidemic, Episode 4: Understanding Old and New Therapies for Diabetes.
    N Engl J Med. 2023;389:e31.
    PubMed    
    
    
    
64. RAMOS EL, Dayan CM, Chatenoud L, Sumnik Z, et al
    Teplizumab and beta-Cell Function in Newly Diagnosed Type 1 Diabetes.
    N Engl J Med. 2023 Oct 18. doi: 10.1056/NEJMoa2308743.
    PubMed     Abstract available
    
    
    
65. LEE TTM, Collett C, Bergford S, Hartnell S, et al
    Automated Insulin Delivery in Women with Pregnancy Complicated by Type 1 Diabetes.
    N Engl J Med. 2023 Oct 5. doi: 10.1056/NEJMoa2303911.
    PubMed     Abstract available
    
    
    
66. GARG SK, Polsky S
    Technology Use and Glycemic Outcomes during Pregnancy with Type 1 Diabetes.
    N Engl J Med. 2023 Oct 5. doi: 10.1056/NEJMe2310798.
    PubMed    
    
    
    
67. ABEL ED, Ingelfinger JR, Linhales Barker S, Lopez D, et al
    Type 2 Diabetes - Controlling the Epidemic, Episode 3: Fostering Patient Engagement and Lifestyle Modifications.
    N Engl J Med. 2023;389:e27.
    PubMed    
    
    
    September 2023
68. ABEL ED, Ingelfinger JR, Kolko J, Linhales Barker S, et al
    Type 2 Diabetes - Controlling the Epidemic, Episode 2: After the Diagnosis - Making a Plan and Addressing Social Determinants of Health.
    N Engl J Med. 2023;389:e23.
    PubMed    
    
    
    
69. DANDONA P, Chaudhuri A, Ghanim H
    Semaglutide in Early Type 1 Diabetes.
    N Engl J Med. 2023;389:958-959.
    PubMed    
    
    
    
70. ABEL ED, Giffin J, Ingelfinger JR, Peek M, et al
    Type 2 Diabetes - Controlling the Epidemic, Episode 1: Understanding and Preventing Type 2 Diabetes.
    N Engl J Med. 2023;389:e18.
    PubMed    
    
    
    August 2023
71. ALI ZA, Landmesser U, Maehara A, Matsumura M, et al
    Optical Coherence Tomography-Guided versus Angiography-Guided PCI.
    N Engl J Med. 2023 Aug 27. doi: 10.1056/NEJMoa2305861.
    PubMed     Abstract available
    
    
    
72. MAGNUSSEN C, Ojeda FM, Leong DP, Alegre-Diaz J, et al
    Global Effect of Modifiable Risk Factors on Cardiovascular Disease and Mortality.
    N Engl J Med. 2023 Aug 26. doi: 10.1056/NEJMoa2206916.
    PubMed     Abstract available
    
    
    
73. KRISCHER JP, Lernmark A, Hagopian WA, Rewers MJ, et al
    SARS-CoV-2 - No Increased Islet Autoimmunity or Type 1 Diabetes in Teens.
    N Engl J Med. 2023;389:474-475.
    PubMed    
    
    
    June 2023
74. JASTREBOFF AM, Kaplan LM, Frias JP, Wu Q, et al
    Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial.
    N Engl J Med. 2023 Jun 26. doi: 10.1056/NEJMoa2301972.
    PubMed     Abstract available
    
    
    
75. ROSENSTOCK J, Bain SC, Gowda A, Jodar E, et al
    Weekly Icodec versus Daily Glargine U100 in Type 2 Diabetes without Previous Insulin.
    N Engl J Med. 2023 Jun 24. doi: 10.1056/NEJMoa2303208.
    PubMed     Abstract available
    
    
    
76. WHARTON S, Blevins T, Connery L, Rosenstock J, et al
    Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity.
    N Engl J Med. 2023 Jun 23. doi: 10.1056/NEJMoa2302392.
    PubMed     Abstract available
    
    
    
77. LINCOFF AM, Bhasin S, Flevaris P, Mitchell LM, et al
    Cardiovascular Safety of Testosterone-Replacement Therapy.
    N Engl J Med. 2023 Jun 16. doi: 10.1056/NEJMoa2215025.
    PubMed     Abstract available
    
    
    
78. WADWA RP, Beck RW, Breton MD
    Hybrid Closed-Loop Control in Young Children with Type 1 Diabetes. Reply.
    N Engl J Med. 2023;388:2206-2207.
    PubMed    
    
    
    
79. SHIBUE K
    Hybrid Closed-Loop Control in Young Children with Type 1 Diabetes.
    N Engl J Med. 2023;388:2206.
    PubMed    
    
    
    
80. HSU NC, Hsu CH
    Hybrid Closed-Loop Control in Young Children with Type 1 Diabetes.
    N Engl J Med. 2023;388:2205-2206.
    PubMed    
    
    
    
81. SANTORO A, Kahn BB
    Adipocyte Regulation of Insulin Sensitivity and the Risk of Type 2 Diabetes.
    N Engl J Med. 2023;388:2071-2085.
    PubMed    
    
    
    May 2023
82. GREENE MF
    Early versus Second-Trimester Screening and Treatment for Diabetes in Pregnancy.
    N Engl J Med. 2023 May 5. doi: 10.1056/NEJMe2304543.
    PubMed    
    
    
    
83. SIMMONS D, Immanuel J, Hague WM, Teede H, et al
    Treatment of Gestational Diabetes Mellitus Diagnosed Early in Pregnancy.
    N Engl J Med. 2023 May 5. doi: 10.1056/NEJMoa2214956.
    PubMed     Abstract available
    
    
    March 2023
84. WEGHUBER D, Kelly AS, Arslanian S
    Once-Weekly Semaglutide in Adolescents with Obesity. Reply.
    N Engl J Med. 2023;388:1146.
    PubMed    
    
    
    
85. MALOZOWSKI S
    Once-Weekly Semaglutide in Adolescents with Obesity.
    N Engl J Med. 2023;388:1145-1146.
    PubMed    
    
    
    
86. SNAITH JR, Greenfield JR
    Once-Weekly Semaglutide in Adolescents with Obesity.
    N Engl J Med. 2023;388:1145.
    PubMed    
    
    
    
87. BRUTTOMESSO D
    Technology in the Changing Management of Diabetes in Children.
    N Engl J Med. 2023;388:1052-1054.
    PubMed    
    
    
    
88. WADWA RP, Reed ZW, Buckingham BA, DeBoer MD, et al
    Trial of Hybrid Closed-Loop Control in Young Children with Type 1 Diabetes.
    N Engl J Med. 2023;388:991-1001.
    PubMed     Abstract available
    
    
    January 2023
89. RUSSELL SJ, Damiano ER, Calhoun P
    Randomized Trial of a Bionic Pancreas in Type 1 Diabetes. Reply.
    N Engl J Med. 2023;388:380-382.
    PubMed    
    
    
    
90. KHOO TK
    Randomized Trial of a Bionic Pancreas in Type 1 Diabetes.
    N Engl J Med. 2023;388:380.
    PubMed    
    
    
    
91. MURATA Y, Takita M, Kami M
    Randomized Trial of a Bionic Pancreas in Type 1 Diabetes.
    N Engl J Med. 2023;388:380.
    PubMed    
    
    
    November 2022
92. BURNSIDE MJ, Williman JA, de Bock MI
    Open-Source Automated Insulin Delivery in Type 1 Diabetes. Reply.
    N Engl J Med. 2022;387:2007-2008.
    PubMed    
    
    
    
93. SCARAMUZZA AE, Cherubini V, Rabbone I
    Open-Source Automated Insulin Delivery in Type 1 Diabetes.
    N Engl J Med. 2022;387:2006-2007.
    PubMed    
    
    
    
94. MURATA Y, Takita M, Kami M
    Open-Source Automated Insulin Delivery in Type 1 Diabetes.
    N Engl J Med. 2022;387:2006.
    PubMed    
    
    
    
95. DAS PRADHAN A, Glynn RJ, Fruchart JC, MacFadyen JG, et al
    Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk.
    N Engl J Med. 2022 Nov 5. doi: 10.1056/NEJMoa2210645.
    PubMed     Abstract available
    
    
    
96. HERRINGTON WG, Staplin N, Wanner C, Green JB, et al
    Empagliflozin in Patients with Chronic Kidney Disease.
    N Engl J Med. 2022 Nov 4. doi: 10.1056/NEJMoa2204233.
    PubMed     Abstract available
    
    
    
97. CROWTHER CA, Tran T
    Lower versus Higher Glycemic Criteria for Diagnosis of Gestational Diabetes. Reply.
    N Engl J Med. 2022;387:1720-1721.
    PubMed    
    
    
    
98. MOHAN V, Unnikrishnan R, Anjana RM
    Lower versus Higher Glycemic Criteria for Diagnosis of Gestational Diabetes.
    N Engl J Med. 2022;387:1720.
    PubMed    
    
    
    
99. RHOADS GG
    Lower versus Higher Glycemic Criteria for Diagnosis of Gestational Diabetes.
    N Engl J Med. 2022;387:1719-1720.
    PubMed    
    
    
    
100. SMITH GCS, Sovio U
     Lower versus Higher Glycemic Criteria for Diagnosis of Gestational Diabetes.
     N Engl J Med. 2022;387:1719.
     PubMed    
     
     
     
101. PAINTER RC, van Rijn BB, Bossuyt PMM
     Lower versus Higher Glycemic Criteria for Diagnosis of Gestational Diabetes.
     N Engl J Med. 2022;387:1718-1719.
     PubMed    
     
     
     October 2022
102. ARSLANIAN SA, Cox D
     Once-Weekly Dulaglutide for Treatment of Youths with Type 2 Diabetes. Reply.
     N Engl J Med. 2022;387:1530-1531.
     PubMed    
     
     
     
103. SENOO Y, Kami M
     Once-Weekly Dulaglutide for Treatment of Youths with Type 2 Diabetes.
     N Engl J Med. 2022;387:1529-1530.
     PubMed    
     
     
     
104. TUTTLE KR, Jones CR, Daratha KB, Koyama AK, et al
     Incidence of Chronic Kidney Disease among Adults with Diabetes, 2015-2020.
     N Engl J Med. 2022;387:1430-1431.
     PubMed    
     
     
     
105. LEELARATHNA L, Evans ML, Neupane S, Rayman G, et al
     Intermittently Scanned Continuous Glucose Monitoring for Type 1 Diabetes.
     N Engl J Med. 2022 Oct 5. doi: 10.1056/NEJMoa2205650.
     PubMed     Abstract available
     
     
     September 2022
106. SHERR J
     Seeking Simpler Solutions with Diabetes Technology.
     N Engl J Med. 2022;387:1228-1229.
     PubMed    
     
     
     
107. RUSSELL SJ, Beck RW, Damiano ER, El-Khatib FH, et al
     Multicenter, Randomized Trial of a Bionic Pancreas in Type 1 Diabetes.
     N Engl J Med. 2022;387:1161-1172.
     PubMed     Abstract available
     
     
     
108. RYDEN L, Standl E
     After Metformin - Next Steps for Type 2 Diabetes with Low Cardiovascular Risk.
     N Engl J Med. 2022;387:1136-1138.
     PubMed    
     
     
     
109. NATHAN DM, Lachin JM, Bebu I, Burch HB, et al
     Glycemia Reduction in Type 2 Diabetes - Microvascular and Cardiovascular Outcomes.
     N Engl J Med. 2022;387:1075-1088.
     PubMed     Abstract available
     
     
     
110. NATHAN DM, Lachin JM, Balasubramanyam A, Burch HB, et al
     Glycemia Reduction in Type 2 Diabetes - Glycemic Outcomes.
     N Engl J Med. 2022;387:1063-1074.
     PubMed     Abstract available
     
     
     
111. BROWN SA
     On the Path toward Expanding Treatment Options for Diabetes.
     N Engl J Med. 2022;387:935-936.
     PubMed    
     
     
     
112. BOUGHTON CK, Allen JM, Ware J, Wilinska ME, et al
     Closed-Loop Therapy and Preservation of C-Peptide Secretion in Type 1 Diabetes.
     N Engl J Med. 2022;387:882-893.
     PubMed     Abstract available
     
     
     
113. BURNSIDE MJ, Lewis DM, Crocket HR, Meier RA, et al
     Open-Source Automated Insulin Delivery in Type 1 Diabetes.
     N Engl J Med. 2022;387:869-881.
     PubMed     Abstract available
     
     
     
114. BOLINDER J
     CLOuDs Disperse - Top-Notch Glucose Control and Residual C-Peptide Secretion.
     N Engl J Med. 2022;387:937-938.
     PubMed    
     
     
     August 2022
115. SOLOMON SD, McMurray JJV, Claggett B, de Boer RA, et al
     Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction.
     N Engl J Med. 2022 Aug 27. doi: 10.1056/NEJMoa2206286.
     PubMed     Abstract available
     
     
     
116. CROWTHER CA, Samuel D, McCowan LME, Edlin R, et al
     Lower versus Higher Glycemic Criteria for Diagnosis of Gestational Diabetes.
     N Engl J Med. 2022;387:587-598.
     PubMed     Abstract available
     
     
     
117. LESLIE BR, Gerwin LE
     Gliflozins in the Management of Cardiovascular Disease.
     N Engl J Med. 2022;387:478.
     PubMed    
     
     
     
118. HEYMAN SN, Abassi Z
     Gliflozins in the Management of Cardiovascular Disease.
     N Engl J Med. 2022;387:477-478.
     PubMed    
     
     
     July 2022
119. MUSCH DC, Chew EY
     Evidence for Step Therapy in Diabetic Macular Edema.
     N Engl J Med. 2022 Jul 14. doi: 10.1056/NEJMe2208454.
     PubMed    
     
     
     
120. JHAVERI CD, Glassman AR, Ferris FL 3rd, Liu D, et al
     Aflibercept Monotherapy or Bevacizumab First for Diabetic Macular Edema.
     N Engl J Med. 2022 Jul 14. doi: 10.1056/NEJMoa2204225.
     PubMed     Abstract available
     
     
     June 2022
121. ARSLANIAN SA, Hannon T, Zeitler P, Chao LC, et al
     Once-Weekly Dulaglutide for the Treatment of Youths with Type 2 Diabetes.
     N Engl J Med. 2022 Jun 4. doi: 10.1056/NEJMoa2204601.
     PubMed     Abstract available
     
     
     
122. JASTREBOFF AM, Aronne LJ, Ahmad NN, Wharton S, et al
     Tirzepatide Once Weekly for the Treatment of Obesity.
     N Engl J Med. 2022 Jun 4. doi: 10.1056/NEJMoa2206038.
     PubMed     Abstract available
     
     
     May 2022
123. BRAUNWALD E
     Gliflozins in the Management of Cardiovascular Disease.
     N Engl J Med. 2022;386:2024-2034.
     PubMed    
     
     
     April 2022
124. PITT B, Joseph A, Schloemer P
     Cardiovascular Events with Finerenone in CKD and Diabetes. Reply.
     N Engl J Med. 2022;386:e43.
     PubMed    
     
     
     
125. ORTIZ A, Sarafidis P, Ferro CJ
     Cardiovascular Events with Finerenone in CKD and Diabetes.
     N Engl J Med. 2022;386:e43.
     PubMed    
     
     
     
126. GERARD AO, Laurain A, Esnault VLM
     Cardiovascular Events with Finerenone in CKD and Diabetes.
     N Engl J Med. 2022;386:e43.
     PubMed    
     
     
     
127. KAO PH, Hsu LC
     Cardiovascular Events with Finerenone in CKD and Diabetes.
     N Engl J Med. 2022;386:e43.
     PubMed    
     
     
     
128. WARE J, Hovorka R
     Closed-Loop Control in Very Young Children with Type 1 Diabetes. Reply.
     N Engl J Med. 2022;386:1482-1483.
     PubMed    
     
     
     
129. RING BL
     Closed-Loop Control in Very Young Children with Type 1 Diabetes.
     N Engl J Med. 2022;386:1482.
     PubMed    
     
     
     
130. MURATA Y, Takita M, Kami M
     Closed-Loop Control in Very Young Children with Type 1 Diabetes.
     N Engl J Med. 2022;386:1482.
     PubMed    
     
     
     March 2022
131. SPERLING MA, Laffel LM
     Current Management of Glycemia in Children with Type 1 Diabetes Mellitus.
     N Engl J Med. 2022;386:1155-1164.
     PubMed    
     
     
     February 2022
132. WING JR, Kimball A, Rengarajan M
     Case 6-2022: A 68-Year-Old Man with Fatigue, Weight Loss, and Hyperglycemia.
     N Engl J Med. 2022;386:781-787.
     PubMed    
     
     
     
133. FRIAS JP, Fernandez Lando L, Brown K
     Tirzepatide versus Semaglutide Once Weekly in Type 2 Diabetes. Reply.
     N Engl J Med. 2022;386:e17.
     PubMed    
     
     
     
134. SANTULLI G
     Tirzepatide versus Semaglutide Once Weekly in Type 2 Diabetes.
     N Engl J Med. 2022;386:e17.
     PubMed    
     
     
     
135. PATOULIAS D, Papadopoulos C, Doumas M
     Tirzepatide versus Semaglutide Once Weekly in Type 2 Diabetes.
     N Engl J Med. 2022;386:e17.
     PubMed    
     
     
     January 2022
136. WARE J, Allen JM, Boughton CK, Wilinska ME, et al
     Randomized Trial of Closed-Loop Control in Very Young Children with Type 1 Diabetes.
     N Engl J Med. 2022;386:209-219.
     PubMed     Abstract available
     
     
     
137. DRAIN PK
     Rapid Diagnostic Testing for SARS-CoV-2.
     N Engl J Med. 2022 Jan 7. doi: 10.1056/NEJMcp2117115.
     PubMed    
     
     
     November 2021
138. GERSTEIN HC, Khurmi NS
     Efpeglenatide and Heart and Kidney Outcomes in Type 2 Diabetes. Reply.
     N Engl J Med. 2021;385:2107.
     PubMed    
     
     
     
139. HE L, Zhang H
     Efpeglenatide and Heart and Kidney Outcomes in Type 2 Diabetes.
     N Engl J Med. 2021;385:2106-2107.
     PubMed    
     
     
     
140. GROOTHOF D, Vogelpohl FA, Bakker SJL
     Efpeglenatide and Heart and Kidney Outcomes in Type 2 Diabetes.
     N Engl J Med. 2021;385:2106.
     PubMed    
     
     
     
141. BORDERIE G, Schnebelen M, Baynat L
     Efpeglenatide and Heart and Kidney Outcomes in Type 2 Diabetes.
     N Engl J Med. 2021;385:2105-2106.
     PubMed    
     
     
     
142. O'CONNELL J, Nathan DM, O'Brien T, O'Keeffe DT, et al
     Treatment of Diabetes - To Pump or Not to Pump.
     N Engl J Med. 2021;385:2092-2095.
     PubMed    
     
     
     
143. BJORNSTAD P, Drews K, Zeitler PS
     Long-Term Complications in Youth-Onset Type 2 Diabetes. Reply.
     N Engl J Med. 2021;385:2016.
     PubMed    
     
     
     
144. NELSON RG, Hanson RL, Knowler WC
     Long-Term Complications in Youth-Onset Type 2 Diabetes.
     N Engl J Med. 2021;385:2015.
     PubMed    
     
     
     
145. YANG W, Wang C
     Long-Term Complications in Youth-Onset Type 2 Diabetes.
     N Engl J Med. 2021;385:2014-2015.
     PubMed    
     
     
     October 2021
146. FRANCQUE SM, Bedossa P, Ratziu V, Anstee QM, et al
     A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH.
     N Engl J Med. 2021;385:1547-1558.
     PubMed     Abstract available
     
     
     August 2021
147. PACKER M, Butler J, Zannad F, Pocock SJ, et al
     Empagliflozin and Major Renal Outcomes in Heart Failure.
     N Engl J Med. 2021 Aug 27. doi: 10.1056/NEJMc2112411.
     PubMed    
     
     

Thank you for your interest in scientific medicine.

AMEDEO Diabetes is free of charge.